Suchbegriffe: LIVER CIRRHOSIS - IMMUNOLOGY , . Treffer: 4
Horvath, A; Leber, B; Schmerboeck, B; Tawdrous, M; Zettel, G; Hartl, A; Madl, T; Stryeck, S; Fuchs, D; Lemesch, S; Douschan, P; Krones, E; Spindelboeck, W; Durchschein, F; Rainer, F; Zollner, G; Stauber, RE; Fickert, P; Stiegler, P; Stadlbauer, V
Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis.
Aliment Pharmacol Ther. 2016; 44(9):926-935
Doi: 10.1111/apt.13788
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Sombetzki, M; Fuchs, CD; Fickert, P; Österreicher, CH; Mueller, M; Claudel, T; Loebermann, M; Engelmann, R; Langner, C; Sahin, E; Schwinge, D; Guenther, ND; Schramm, C; Mueller-Hilke, B; Reisinger, EC; Trauner, M
24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
J Hepatol. 2015; 62(4):871-878
Doi: 10.1016/j.jhep.2014.11.020
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Leber, B; Spindelboeck, W; Stadlbauer, V
Infectious complications of acute and chronic liver disease.
Semin Respir Crit Care Med. 2012; 33(1):80-95
Doi: 10.1055/s-0032-1301737
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Stadlbauer, V; Davies, NA; Wright, G; Jalan, R
Endotoxin measures in patients' sample: how valid are the results?
J Hepatol. 2007; 47(5): 726-727.
Doi: 10.1016/j.jhep.2007.08.001
Web of Science
PubMed
FullText
FullText_MUG